BRPI0908494A2 - Inibidores de pirrolopirazina quinase - Google Patents

Inibidores de pirrolopirazina quinase

Info

Publication number: BRPI0908494A2
Authority: BR; Brazil
Prior art keywords: kinase inhibitors; pyrrolopyrazine; pyrrolopyrazine kinase; inhibitors; kinase
Prior art date: 2008-02-25

Application number

BRPI0908494-0A

Other languages

English (en)

Inventor

Joe Timothy Bamberg

Mark Bartlett

Daisy Joe Du Bois

Todd Richard Elworthy

Robert Than Hendricks

Johannes Cornelius Hermann

Rama K Kondru

Remy Lemoine

Yan Lou

Timothy D Owens

Jaehyeon Park

David Bernard Smith

Michael Soth

Hanbiao Yang

Calvin Wesley Yee

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-02-25

Filing date

2009-02-16

Publication date

2015-08-11

2009-02-16 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2015-08-11 Publication of BRPI0908494A2 publication Critical patent/BRPI0908494A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Neurology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

BRPI0908494-0A 2008-02-25 2009-02-16 Inibidores de pirrolopirazina quinase BRPI0908494A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US3103508P	2008-02-25	2008-02-25
US20572409P	2009-01-22	2009-01-22
PCT/EP2009/051757 WO2009106442A1 (en)	2008-02-25	2009-02-16	Pyrrolopyrazine kinase inhibitors

Publications (1)

Publication Number	Publication Date
BRPI0908494A2 true BRPI0908494A2 (pt)	2015-08-11

Family

ID=40514094

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0908494-0A BRPI0908494A2 (pt)	2008-02-25	2009-02-16	Inibidores de pirrolopirazina quinase

Country Status (20)

Country	Link
US (1)	US7939531B2 (pt)
EP (1)	EP2247592B1 (pt)
JP (1)	JP5368485B2 (pt)
KR (1)	KR101261514B1 (pt)
CN (1)	CN101939324B (pt)
AR (1)	AR070468A1 (pt)
AT (1)	ATE522535T1 (pt)
AU (1)	AU2009218607B2 (pt)
BR (1)	BRPI0908494A2 (pt)
CA (1)	CA2713710A1 (pt)
CL (1)	CL2009000406A1 (pt)
DK (1)	DK2247592T3 (pt)
IL (1)	IL206358A0 (pt)
MX (1)	MX2010008198A (pt)
PE (1)	PE20091493A1 (pt)
PL (1)	PL2247592T3 (pt)
PT (1)	PT2247592E (pt)
RU (1)	RU2503676C2 (pt)
TW (1)	TWI380987B (pt)
WO (1)	WO2009106442A1 (pt)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2250172T3 (da) *	2008-02-25	2012-01-16	Hoffmann La Roche	Pyrrolopyrazinkinaseinhibitorer
CA2716223A1 (en) *	2008-02-25	2009-09-03	F. Hoffmann-La Roche Ag	Pyrrolopyrazine kinase inhibitors
CN101952295B (zh) *	2008-02-25	2013-11-20	霍夫曼-拉罗奇有限公司	吡咯并吡嗪激酶抑制剂
ATE519763T1 (de) *	2008-02-25	2011-08-15	Hoffmann La Roche	Pyrrolopyrazin-kinasehemmer
PE20110223A1 (es) *	2008-06-10	2011-05-07	Abbvie Inc	DERIVADOS DE PIRROLO[2,3-e][1,2,4]TRIAZOLO[4,3-a]PIRAZIN, COMO INHIBIDORES DE QUINASA
WO2010054398A1 (en)	2008-11-10	2010-05-14	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
EP3037421A3 (en)	2008-11-25	2016-11-30	University Of Rochester	Mlk inhibitors and methods of use
CA3013000C (en)	2008-12-19	2022-12-13	Vertex Pharmaceuticals Incorporated	Pyrazine derivatives useful as inhibitors of atr kinase
PE20120508A1 (es)	2009-06-17	2012-05-09	Vertex Pharma	Inhibidores de la replicacion de los virus de la gripe
CN102596962A (zh) *	2009-09-10	2012-07-18	弗·哈夫曼-拉罗切有限公司	Jak抑制剂
WO2011068881A1 (en)	2009-12-01	2011-06-09	Abbott Laboratories	Novel tricyclic compounds
EP2506713A4 (en)	2009-12-01	2014-09-03	Abbvie Inc	NEW TRICYCLIC COMPOUNDS
EP2338888A1 (en) *	2009-12-24	2011-06-29	Almirall, S.A.	Imidazopyridine derivatives as JAK inhibitors
RU2012136451A (ru)	2010-01-28	2014-03-10	Президент Энд Феллоуз Оф Гарвард Колледж	Композиции и способы улучшения активности протеасомы
UY33213A (es)	2010-02-18	2011-09-30	Almirall Sa	Derivados de pirazol como inhibidores de jak
US8518945B2 (en)	2010-03-22	2013-08-27	Hoffmann-La Roche Inc.	Pyrrolopyrazine kinase inhibitors
US8481541B2 (en) *	2010-03-22	2013-07-09	Hoffmann-La Roche Inc.	Pyrrolopyrazine kinase inhibitors
JP2013526538A (ja)	2010-05-12	2013-06-24	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｒキナーゼ阻害剤として有用な化合物
EP2569286B1 (en)	2010-05-12	2014-08-20	Vertex Pharmaceuticals Inc.	Compounds useful as inhibitors of atr kinase
NZ603477A (en)	2010-05-12	2014-09-26	Vertex Pharma	Compounds useful as inhibitors of atr kinase
US9334244B2 (en)	2010-05-12	2016-05-10	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
NZ603478A (en)	2010-05-12	2014-09-26	Vertex Pharma	2 -aminopyridine derivatives useful as inhibitors of atr kinase
EP2569289A1 (en)	2010-05-12	2013-03-20	Vertex Pharmaceuticals Incorporated	Pyrazines useful as inhibitors of atr kinase
TWI496785B (zh) *	2010-05-20	2015-08-21	Hoffmann La Roche	吡咯并吡激酶抑制劑
RU2012152352A (ru) *	2010-05-20	2014-06-27	Ф. Хоффманн-Ля Рош Аг	ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-b]ПИРАЗИН-7-КАРБОКСАМИДА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ JAK И SYK
CN103153994B (zh) *	2010-05-24	2016-02-10	罗切斯特大学	双环杂芳基激酶抑制剂及使用方法
WO2011163527A1 (en)	2010-06-23	2011-12-29	Vertex Pharmaceuticals Incorporated	Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
EP2463289A1 (en)	2010-11-26	2012-06-13	Almirall, S.A.	Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
DE102011009961A1 (de) *	2011-02-01	2012-08-02	Merck Patent Gmbh	7-Azaindolderivate
KR20140027974A (ko)	2011-04-05	2014-03-07	버텍스 파마슈티칼스 인코포레이티드	Ｔｒａ 키나제의 억제제로서 유용한 아미노피라진 화합물
HRP20190867T1 (hr)	2011-05-12	2019-07-12	Proteostasis Therapeutics, Inc.	Regulatori proteostaze
MX2013013331A (es)	2011-05-17	2014-10-17	Principia Biopharma Inc	Derivados de azaindol como inhibidores de tirosina-cinasas.
US9309250B2 (en)	2011-06-22	2016-04-12	Vertex Pharmaceuticals Incorporated	Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
WO2012178123A1 (en)	2011-06-22	2012-12-27	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
WO2012178124A1 (en) *	2011-06-22	2012-12-27	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
JP2014520815A (ja) *	2011-07-05	2014-08-25	バーテックスファーマシューティカルズインコーポレイテッド	アザインドールを作製するための方法および中間体
EP2554544A1 (en)	2011-08-01	2013-02-06	Almirall, S.A.	Pyridin-2(1h)-one derivatives as jak inhibitors
UA118010C2 (uk)	2011-08-01	2018-11-12	Вертекс Фармасьютікалз Інкорпорейтед	Інгібітори реплікації вірусів грипу
CN104024258B (zh) *	2011-09-01	2017-02-15	霍夫曼-拉罗奇有限公司	吡咯并吡嗪激酶抑制剂
KR20140074912A (ko) *	2011-09-01	2014-06-18	에프. 호프만-라 로슈 아게	피롤로피라진 키나아제 억제제
CN103957917A (zh)	2011-09-30	2014-07-30	沃泰克斯药物股份有限公司	用atr抑制剂治疗胰腺癌和非小细胞肺癌
EP2751088B1 (en)	2011-09-30	2016-04-13	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
EP3878851A1 (en)	2011-09-30	2021-09-15	Vertex Pharmaceuticals Incorporated	Process for making compounds useful as inhibitors of atr kinase
KR20140084112A (ko)	2011-09-30	2014-07-04	버텍스 파마슈티칼스 인코포레이티드	Ａｔｒ 키나제의 억제제로서 유용한 화합물
US8853217B2 (en)	2011-09-30	2014-10-07	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
EP2773645A1 (en)	2011-11-01	2014-09-10	F.Hoffmann-La Roche Ag	Imidazopyridazine compounds
EP2776420A1 (en)	2011-11-09	2014-09-17	Vertex Pharmaceuticals Incorporated	Pyrazine compounds useful as inhibitors of atr kinase
WO2013071094A1 (en)	2011-11-09	2013-05-16	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
WO2013071088A1 (en)	2011-11-09	2013-05-16	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
EP2776419B1 (en)	2011-11-09	2016-05-11	Vertex Pharmaceuticals Incorporated	Pyrazine compounds useful as inhibitors of atr kinase
WO2013071090A1 (en)	2011-11-09	2013-05-16	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
KR20140108594A (ko)	2012-01-10	2014-09-11	에프. 호프만-라 로슈 아게	피리다진 아미드 화합물 및 syk 저해제로서의 이의 용도
HK1205028A1 (en)	2012-04-05	2015-12-11	沃泰克斯药物股份有限公司	Compounds useful as inhibitors of atr kinase and combination therapies thereof
WO2014029732A1 (en) *	2012-08-21	2014-02-27	F. Hoffmann-La Roche Ag	Pyrrolo[2,3-b]pyrazines as syk inhibitors
EP3181567B9 (en)	2012-09-10	2025-09-24	Principia Biopharma Inc.	Pyrazolopyrimidine compounds as kinase inhibitors
EP2904406B1 (en)	2012-10-04	2018-03-21	Vertex Pharmaceuticals Incorporated	Method for measuring atr inhibition mediated increases in dna damage
WO2014062604A1 (en)	2012-10-16	2014-04-24	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
AU2013348116A1 (en)	2012-11-20	2015-06-11	Principia Biopharma Inc.	Azaindole derivatives as JAK3 inhibitors
WO2014085795A1 (en)	2012-11-30	2014-06-05	University Of Rochester	Mixed lineage kinase inhibitors for hiv/aids therapies
HRP20180859T1 (hr)	2012-12-07	2018-07-13	Vertex Pharmaceuticals Incorporated	2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oksetan-3-il)piperazin-1-karbonil)piperidin-1-il)piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze
WO2014116228A1 (en)	2013-01-25	2014-07-31	President And Fellows Of Harvard College	Usp14 inhibitors for treating or preventing viral infections
EP2970286A1 (en)	2013-03-15	2016-01-20	Vertex Pharmaceuticals Inc.	Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
CN105209435B (zh) *	2013-05-14	2018-02-02	3M创新有限公司	包含吡啶或吡嗪的化合物
US9296727B2 (en)	2013-10-07	2016-03-29	Vertex Pharmaceuticals Incorporated	Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
WO2015073528A1 (en)	2013-11-12	2015-05-21	Proteostasis Therapeutics, Inc.	Proteasome activity enhancing compounds
SI3421468T1 (sl)	2013-11-13	2021-03-31	Vertex Pharmaceuticals Incorporated	Postopki za pripravo inhibitorjev replikacije virusov influence
EP3074025A1 (en)	2013-11-27	2016-10-05	Baylor College Of Medicine	Csgp4-specific chimeric antigen receptor for cancer
CN103665803B (zh) *	2013-12-05	2015-07-01	湖南大学	一种基于金属环钯化合物的结晶聚乳酸及其制备方法和金属环钯化合物的应用
HRP20192183T1 (hr)	2013-12-06	2020-02-21	Vertex Pharmaceuticals Inc.	Spoj 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-karboksamida koristan kao inhibitor atr kinase, njegova priprava, različiti kruti oblici te njegovi radioaktivno označeni derivati
KR20160117614A (ko)	2014-02-21	2016-10-10	프린시피아 바이오파마, 인코퍼레이티드	Btk 억제제의 염 및 고체 형태
EP3152212B9 (en)	2014-06-05	2020-05-27	Vertex Pharmaceuticals Inc.	Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
EP3157566B1 (en)	2014-06-17	2019-05-01	Vertex Pharmaceuticals Incorporated	Method for treating cancer using a combination of chk1 and atr inhibitors
WO2016004413A2 (en) *	2014-07-03	2016-01-07	Board Of Regents, University Of Texas System	Gls1 inhibitors for treating disease
EP3164394B1 (en)	2014-07-03	2020-04-01	Board of Regents, The University of Texas System	Gls1 inhibitors for treating diseases
CA2970723C (en)	2014-12-18	2023-09-05	Principia Biopharma Inc.	Treatment of pemphigus
WO2016178110A1 (en) *	2015-05-01	2016-11-10	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof
EP3294735B8 (en)	2015-05-13	2022-01-05	Vertex Pharmaceuticals Incorporated	Inhibitors of influenza viruses replication
WO2016183116A1 (en)	2015-05-13	2016-11-17	Vertex Pharmaceuticals Incorporated	Methods of preparing inhibitors of influenza viruses replication
EP3313839A1 (en)	2015-06-24	2018-05-02	Principia Biopharma Inc.	Tyrosine kinase inhibitors
ES2794868T3 (es)	2015-06-30	2020-11-19	Univ Texas	Inhibidores de GLS1 para el tratamiento de enfermedades
HK1258570A1 (zh)	2015-09-30	2019-11-15	Vertex Pharmaceuticals Inc.	使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
US20170100396A1 (en)	2015-10-07	2017-04-13	F. Hoffmann-La Roche Ag	Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza
SG11201802990RA (en)	2015-10-16	2018-05-30	Abbvie Inc	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US12365689B2 (en)	2015-10-16	2025-07-22	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en)	2015-10-16	2022-12-13	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en)	2015-10-16	2022-06-21	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en)	2015-10-16	2023-10-03	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en)	2015-10-16	2020-02-04	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en)	2015-10-16	2022-11-29	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
BR112018012660B1 (pt)	2015-12-22	2023-12-19	Board Of Regents, The University Of Texas System	Sal, solvato, ou polimorfo de um composto; polimorfo de composto sólido; composição; e uso de um sal, solvato ou polimorfo
US20190231784A1 (en)	2016-06-29	2019-08-01	Principia Biopharma Inc.	Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2018177993A1 (de)	2017-03-31	2018-10-04	Bayer Cropscience Aktiengesellschaft	Pyrazole zur bekämpfung von arthropoden
WO2019079632A1 (en)	2017-10-18	2019-04-25	Board Of Regents, The University Of Texas System	GLUTAMINASE INHIBITOR THERAPY
EP3720441A1 (en) *	2017-12-04	2020-10-14	H. Hoffnabb-La Roche Ag	Pyrrolo[2,3-b]pyrazine compounds as cccdna inhibitors for the treatment of hepatitis b virus (hbv) infection
MX2020007031A (es) *	2018-01-05	2020-12-03	Ac Immune Sa	Derivados de 1,3,4,5-tetrahidro -2 h-pirido [4,3-b] indol para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau tales como la enfermedad de alzheimer.
CN114341145B (zh) *	2019-07-03	2024-08-16	博拉公司	化学化合物
TW202543647A (zh)	2019-10-14	2025-11-16	美商普林斯匹亞生物製藥公司	藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌𠯤-1-基]戊-2-烯腈來治療免疫血小板減少症之方法
JP2023507138A (ja)	2019-12-20	2023-02-21	ファイザー・インク	ベンゾイミダゾール誘導体
AU2021209884A1 (en)	2020-01-22	2022-09-15	Principia Biopharma Inc.	Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2023025109A1 (zh) *	2021-08-23	2023-03-02	上海维申医药有限公司	一类Toll样受体抑制剂及其制备和应用
EP4644396A1 (en) *	2022-12-28	2025-11-05	Visionpharma (Nantong) Co., Ltd	Toll-like receptor inhibitor, and preparation therefor and application thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20000885B1 (hr) *	1998-06-19	2007-03-31	Pfizer Products Inc.	PIROLO[2,3-d]PIRIMIDINSKI SPOJEVI
CN1615873A (zh) *	1999-12-24	2005-05-18	阿文蒂斯药物有限公司	氮杂吲哚类化合物
GB0115109D0 (en) *	2001-06-21	2001-08-15	Aventis Pharma Ltd	Chemical compounds
DE60316542T2 (de) *	2002-03-28	2008-07-03	Eisai R&D Management Co., Ltd.	7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen
US20070066641A1 (en) *	2003-12-19	2007-03-22	Prabha Ibrahim	Compounds and methods for development of RET modulators
PL1696920T3 (pl)	2003-12-19	2015-03-31	Plexxikon Inc	Związki i sposoby opracowywania modulatorów Ret
US7626021B2 (en) *	2004-07-27	2009-12-01	Sgx Pharmaceuticals, Inc.	Fused ring heterocycle kinase modulators
EP1778687A2 (en) *	2004-07-27	2007-05-02	SGX Pharmaceuticals, Inc.	Fused ring heterocycle kinase modulators
EP1814883A1 (en) *	2004-11-22	2007-08-08	Vertex Pharmaceuticals Incorporated	Bicyclic inhibitors or rho kinase
US7456289B2 (en)	2004-12-31	2008-11-25	National Health Research Institutes	Anti-tumor compounds
WO2007015866A2 (en) *	2005-07-20	2007-02-08	Kalypsys, Inc.	Inhibitors of p38 kinase and methods of treating inflammatory disorders
CL2007002617A1 (es)	2006-09-11	2008-05-16	Sanofi Aventis	Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
WO2008063888A2 (en) *	2006-11-22	2008-05-29	Plexxikon, Inc.	Compounds modulating c-fms and/or c-kit activity and uses therefor
PE20121126A1 (es) *	2006-12-21	2012-08-24	Plexxikon Inc	Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa

2009
- 2009-02-16 PL PL09713736T patent/PL2247592T3/pl unknown
- 2009-02-16 MX MX2010008198A patent/MX2010008198A/es active IP Right Grant
- 2009-02-16 DK DK09713736.8T patent/DK2247592T3/da active
- 2009-02-16 JP JP2010548069A patent/JP5368485B2/ja not_active Expired - Fee Related
- 2009-02-16 KR KR1020107018678A patent/KR101261514B1/ko not_active Expired - Fee Related
- 2009-02-16 AU AU2009218607A patent/AU2009218607B2/en not_active Ceased
- 2009-02-16 AT AT09713736T patent/ATE522535T1/de active
- 2009-02-16 CN CN200980104705.5A patent/CN101939324B/zh not_active Expired - Fee Related
- 2009-02-16 PT PT09713736T patent/PT2247592E/pt unknown
- 2009-02-16 CA CA2713710A patent/CA2713710A1/en not_active Abandoned
- 2009-02-16 BR BRPI0908494-0A patent/BRPI0908494A2/pt not_active IP Right Cessation
- 2009-02-16 RU RU2010139566/04A patent/RU2503676C2/ru not_active IP Right Cessation
- 2009-02-16 EP EP09713736A patent/EP2247592B1/en not_active Not-in-force
- 2009-02-16 WO PCT/EP2009/051757 patent/WO2009106442A1/en not_active Ceased
- 2009-02-20 US US12/378,978 patent/US7939531B2/en not_active Expired - Fee Related
- 2009-02-23 AR ARP090100621A patent/AR070468A1/es unknown
- 2009-02-23 CL CL2009000406A patent/CL2009000406A1/es unknown
- 2009-02-23 TW TW098105681A patent/TWI380987B/zh not_active IP Right Cessation
- 2009-02-23 PE PE2009000259A patent/PE20091493A1/es not_active Application Discontinuation
2010
- 2010-06-14 IL IL206358A patent/IL206358A0/en unknown

Also Published As

Publication number	Publication date
RU2503676C2 (ru)	2014-01-10
US7939531B2 (en)	2011-05-10
WO2009106442A1 (en)	2009-09-03
KR20100114094A (ko)	2010-10-22
EP2247592A1 (en)	2010-11-10
PL2247592T3 (pl)	2012-01-31
JP5368485B2 (ja)	2013-12-18
RU2010139566A (ru)	2012-04-10
TW200938547A (en)	2009-09-16
KR101261514B1 (ko)	2013-05-07
DK2247592T3 (da)	2011-09-26
JP2011513262A (ja)	2011-04-28
IL206358A0 (en)	2010-12-30
ATE522535T1 (de)	2011-09-15
AU2009218607A1 (en)	2009-09-03
PE20091493A1 (es)	2009-09-25
CN101939324A (zh)	2011-01-05
EP2247592B1 (en)	2011-08-31
AR070468A1 (es)	2010-04-07
TWI380987B (zh)	2013-01-01
CN101939324B (zh)	2014-10-15
PT2247592E (pt)	2011-11-03
MX2010008198A (es)	2010-08-23
AU2009218607B2 (en)	2014-02-13
CL2009000406A1 (es)	2010-09-21
CA2713710A1 (en)	2009-09-03
US20090215750A1 (en)	2009-08-27

Publication	Publication Date	Title
BRPI0908494A2 (pt)	2015-08-11	Inibidores de pirrolopirazina quinase
ATE519763T1 (de)	2011-08-15	Pyrrolopyrazin-kinasehemmer
CY2020023I1 (el)	2020-11-25	Αναστολεiς βητα-λακταμασων
CY2019009I1 (el)	2019-11-27	Αναστολεις πρωτεϊνικων κινασων
HUS1900029I1 (hu)	2020-04-28	Kináz inhibitor foszforszármazékok
BRPI0920135A2 (pt)	2019-09-24	imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI0913879A2 (pt)	2019-09-24	fenilpirazinonas como inibidores de quinase
BRPI0918846A2 (pt)	2019-09-24	inibidores de cinase heterocíclica
BRPI0922880A2 (pt)	2018-07-24	compostos inibidores de quinase
BRPI0910668A2 (pt)	2019-09-24	inibidores de proteína quinases
BRPI0922937A2 (pt)	2019-09-24	inibidores de pirrolopirazinil uréia quinase
BRPI0814797A2 (pt)	2015-02-03	Inibidores dna-pk
EP2498607A4 (en)	2013-06-19	Kinase Inhibitors
EP2493313A4 (en)	2013-05-15	Kinase Inhibitors
BRPI0913580A2 (pt)	2015-10-20	pirrolopiridinas como inibidores de quinase
BRPI0922962A2 (pt)	2019-09-24	inibidores de p38 map quinase
EP2558099A4 (en)	2013-07-17	Kinase inhibitors
BRPI0906838A2 (pt)	2015-07-14	Pirimidinas como inibidores de quinase
BRPI0912475A2 (pt)	2018-01-09	compostos como inibidores de quinase
BRPI0918564A2 (pt)	2015-12-01	inibidores
EP2515657A4 (en)	2013-07-03	Tyrosine kinase inhibitor
BRPI0914936A2 (pt)	2015-10-20	naftiridininonas como inibidores de aurora quinase
BRPI0716198A2 (pt)	2013-11-12	Pirrolo-isoquinolinas como inibidores de cinase
DK2170891T3 (da)	2011-12-12	Pyrazolopyrimidinon-kinasehæmmere
BRPI0912564A2 (pt)	2019-09-24	inibidores de jnk

Legal Events

Date	Code	Title	Description
2016-12-20	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 8A ANUIDADE.
2017-04-04	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]